IgA levels in lung and serum after oral immunisation with BCG encapsulated in alginate microspheres
Abstract number: P650
Hosseini M., Ajdari S., Adli Moghadam A.
Introduction: BCG is the only available vaccine for prevention of tuberculosis. In tuberculosis induction of concurrent mucosal and systemic immunity protective against both pulmonary infection and systemic disease progression is desired. BCG is currently administered parenterally, which primarily stimulates systemic immune responses. Mucosal administration of vaccine offers the ability to trigger both mucosal and systemic immune responses.
Materials and Methods: In the present study, BALB/c mice were vaccinated orally with BCG encapsulated in alginate microspheres, then IgG and IgA levels in sera and lung homogenates, and DTH response were compared with those of mice vaccinated with free BCG by subcutaneous route.
Results: Mice immunised with encapsulated BCG and those immunised subcutaneously with BCG developed comparable DTH responses. IgA level in lung homogenate was significantly higher in the group immunised with encapsulated BCG than the group immunised with BCG subcutaneously. IgG level in lung homogenate was similar between two vaccinated groups. Serum IgG level was significantly higher in the group subcutaneously immunised than the group orally immunised with BCG, however immunisation with BCG either orally or subcutaneously produce similar level of IgA in serum.
Conclusion: Our data indicate that oral administration of BCG in alginate microspheres results in both systemic and mucosal immune responses.
|Session name:||19th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Helsinki, Finland, 16 - 19 May 2009|
|Back to top|